These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 24638136)

  • 1. Neuro-oncology: Bevacizumab prolongs progression-free survival but not overall survival in newly diagnosed glioblastoma.
    Malkki H
    Nat Rev Neurol; 2014 Apr; 10(4):179. PubMed ID: 24638136
    [No Abstract]   [Full Text] [Related]  

  • 2. Bevacizumab for newly diagnosed glioblastoma.
    Chinot OL; Wick W; Cloughesy T
    N Engl J Med; 2014 May; 370(21):2049. PubMed ID: 24860870
    [No Abstract]   [Full Text] [Related]  

  • 3. Bevacizumab for newly diagnosed glioblastoma.
    Haines IE; Gabor Miklos GL
    N Engl J Med; 2014 May; 370(21):2048. PubMed ID: 24849089
    [No Abstract]   [Full Text] [Related]  

  • 4. Bevacizumab in glioblastoma--still much to learn.
    Fine HA
    N Engl J Med; 2014 Feb; 370(8):764-5. PubMed ID: 24552324
    [No Abstract]   [Full Text] [Related]  

  • 5. Neuro-oncology: What is the optimal use of bevacizumab in glioblastoma?
    Desjardins A
    Nat Rev Neurol; 2015 Aug; 11(8):429-30. PubMed ID: 26195258
    [No Abstract]   [Full Text] [Related]  

  • 6. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
    Chinot OL; Wick W; Mason W; Henriksson R; Saran F; Nishikawa R; Carpentier AF; Hoang-Xuan K; Kavan P; Cernea D; Brandes AA; Hilton M; Abrey L; Cloughesy T
    N Engl J Med; 2014 Feb; 370(8):709-22. PubMed ID: 24552318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential novel role of bevacizumab in glioblastoma and cervical cancer.
    Goey AK; Figg WD
    Cancer Biol Ther; 2014 Oct; 15(10):1296-8. PubMed ID: 25046485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reply to T.J. Kruser et al.
    Chinot OL; Taphoorn MJ; Bais C; Bourgon R; Phillips HS; Abrey LE; Wick W; Mason W; Henriksson R; Saran F; Nishikawa R; Cloughesy T
    J Clin Oncol; 2016 Apr; 34(11):1282-3. PubMed ID: 26884575
    [No Abstract]   [Full Text] [Related]  

  • 9. A randomized trial of bevacizumab for newly diagnosed glioblastoma.
    Gilbert MR; Dignam JJ; Armstrong TS; Wefel JS; Blumenthal DT; Vogelbaum MA; Colman H; Chakravarti A; Pugh S; Won M; Jeraj R; Brown PD; Jaeckle KA; Schiff D; Stieber VW; Brachman DG; Werner-Wasik M; Tremont-Lukats IW; Sulman EP; Aldape KD; Curran WJ; Mehta MP
    N Engl J Med; 2014 Feb; 370(8):699-708. PubMed ID: 24552317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Patients Who Benefit From Bevacizumab in High-Grade Glioma-An Easy Question Turned Difficult: Treat the Scan or the Patient?
    Kruser TJ; Mehta MP; Kozak KR
    J Clin Oncol; 2016 Apr; 34(11):1281-2. PubMed ID: 26884565
    [No Abstract]   [Full Text] [Related]  

  • 11. Bevacizumab for glioblastoma multiforme after traumatic subarachnoid hemorrhage.
    Lukas RV; Goldenberg F; Nicholas MK
    J Clin Neurosci; 2012 Sep; 19(9):1310-1. PubMed ID: 22721885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab for newly diagnosed glioblastoma.
    Gilbert MR; Sulman EP; Mehta MP
    N Engl J Med; 2014 May; 370(21):2048-9. PubMed ID: 24849088
    [No Abstract]   [Full Text] [Related]  

  • 13. Targeted therapies: Further delineating bevacizumab's response spectrum.
    Reardon DA; Wen PY
    Nat Rev Clin Oncol; 2014 May; 11(5):243-4. PubMed ID: 24710578
    [No Abstract]   [Full Text] [Related]  

  • 14. Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma.
    Lou E; Peters KB; Sumrall AL; Desjardins A; Reardon DA; Lipp ES; Herndon JE; Coan A; Bailey L; Turner S; Friedman HS; Vredenburgh JJ
    Cancer Med; 2013 Apr; 2(2):185-95. PubMed ID: 23634286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma.
    Hainsworth JD; Shih KC; Shepard GC; Tillinghast GW; Brinker BT; Spigel DR
    Clin Adv Hematol Oncol; 2012 Apr; 10(4):240-6. PubMed ID: 22706484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab as secondline treatment of glioblastoma -  worth the effort?
    Rovere RK
    Klin Onkol; 2014; 27(3):219-20. PubMed ID: 24918282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiangiogenic therapy for high-grade glioma.
    Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
    Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab therapy for glioblastoma: a passionate discussion.
    Desjardins A; Friedman HS
    CNS Oncol; 2014 Jan; 3(1):1-3. PubMed ID: 25054891
    [No Abstract]   [Full Text] [Related]  

  • 19. Questions regarding the optimal use of bevacizumab in glioblastoma: a moving target.
    Stupp R; Weller M
    Neuro Oncol; 2014 Jun; 16(6):765-7. PubMed ID: 24826844
    [No Abstract]   [Full Text] [Related]  

  • 20. Is deferred use of bevacizumab for glioblastoma associated with prolonged survival?
    D'Alessandris QG; Capo G; Pallini R
    Neuro Oncol; 2014 Oct; 16(10):1427. PubMed ID: 25053854
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.